David S. Memel Joins Company as Chief Medical Officer; Frank E. Fee III is Promoted to Chief Financial Officer

RESEARCH TRIANGLE PARK, N.C. – January 26, 2017 – Metabolon, Inc., the global leader in metabolomics, announced changes today to its executive team. David S. Memel, MD, MS, MBA, has joined Metabolon as its Chief Medical Officer to provide medical leadership in delivering the company’s Precision Medicine products, and Frank E. Fee III has been promoted to Chief Financial Officer.

Dr. Memel has more than 25 years’ experience spanning U.S. and global pharmaceutical, diagnostics, payer and provider organizations. Prior to joining Metabolon, he was the Managing Director of Klaipeda Health, a healthcare and life sciences advisory company. He has held a variety of commercial, medical, scientific, informatics and technology leadership positions at Boehringer Ingelheim Pharmaceuticals, Aetna, Roche Diagnostics, Roche Pharmaceuticals and PeaceHealth (a multi-state healthcare delivery system). He also has advised start-up, mid-size and global healthcare and life sciences organizations in the areas of innovation, product and service development, and the use of healthcare analytics and real-world evidence for accelerating research, improving healthcare and driving business value.

“We’re pleased to have David join our leadership team,” said John Ryals, PhD, Metabolon CEO. “He has made significant contributions to the development and commercialization of many pharmaceutical and diagnostic products; led development and implementation of a variety of healthcare and life sciences technologies, analytics and evidence-based services and solutions; and built and led high-performing teams to deliver new capabilities and value. I am confident that his broad experience will help us build the clinical capabilities that are critical to achieving Metabolon’s Precision Medicine vision.”

Mr. Fee has been with Metabolon since 2011, where he has assumed increasing levels of leadership across the organization and is now responsible for overseeing all activities and relationships related to finance, accounting, planning and treasury functions. His most recent position was Senior Vice President, Finance. In 2016, he led financings of $30 million in equity that added Essex Woodlands as a new investor and $25 million in long-term debt. Prior to joining Metabolon, Mr. Fee was in the Life Sciences practice of Ernst & Young and is a Certified Public Accountant.

Ryals added: “Frank has demonstrated his finance and accounting expertise and a deep understanding of our industry and company. As Chief Financial Officer, I know that he will continue to be a strong financial and strategic partner as we continue to grow our business.”

About Metabolon
Metabolon, Inc. is the world’s leading health technology company focused on the use of metabolomics in precision medicine and life sciences research. This powerful tool for assessing health is based on proprietary platforms and informatics that deliver biomarker discoveries, innovative diagnostic tests, and ground-breaking partnerships in genomics-based health initiatives. Metabolon’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. The company was founded in 2000 and is headquartered in Research Triangle Park, North Carolina. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter.

Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove to be incorrect, Metabolon’s results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; the clinical utility of Metabolon’s metabolomic services; Metabolon’s and its distributors’ ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including access, pricing and reimbursement of diagnostic tests; the strength of Metabolon’s intellectual property portfolio; Metabolon’s history of operating losses; whether Metabolon is able to achieve or sustain profitability; its highly competitive industry; its ability to compete effectively; security and privacy risks; and Metabolon’s ability to continue to innovate and provide products and services that are useful to its clients, among other risks, uncertainties and assumptions.


Robin Fastenau
Vice President, Corporate Communications & Investor Relations
Metabolon, Inc.